Netilmicin, a semisynthetic derivative of sisomicin, was tested in vitro against 600 clinical bacterial isolates. At a concentration of 1.56 ,ug/ml, over 90% of gram-negative bacilli were inhibited. Netilmicin was substantially more active against isolates ofSerratia marcescens and Enterobacter spp. than gentamicin, sisomicin, tobramycin, or amikacin. Isolates of Staphylococcus aureus (both penicillin G susceptible and resistant) were quite susceptible to netilmicin. Most isolates of Klebsiella spp. and Serratia spp. and some of the isolates of Pseudomonas aeruginosa that were resistant to gentamicin proved to be susceptible to netilmicin.
Gram-negative bacilli are responsible for an increasing number of infections in hospitalized patients (2) . Aminoglycoside antibiotics, such as gentamicin, amikacin, and tobramycin, have been quite successful in the treatment of gram-negative infections. However, increased resistance to these antibiotics has developed in recent years (6, 7) . Recently, a new aminoglycoside, netilmicin, has been synthesized from sisomicin, which is produced by Micromonospora inyoensis. It has a spectrum of in vitro activity that is similar to gentamicin sulfate. We determined the activity of netilmicin against clinical bacterial isolates and compared its activity with that of gentamicin, sisomicin, tobramycin, and amikacin. The activity of netilmicin was also determined against gentamicin-resistant isolates of gram-negative bacilli.
MATERIALS AND METHODS Susceptibility tests were conducted on 497 gramnegative bacilli and 103 gram-positive cocci, u,sing the dilution technique with an automatic microtiter system (Autotiter Instruction Manual, Canalco). All isolates of gram-negative bacilli and Staphylococcus aureus were inoculated into Mueller-Hinton broth (Difco) and incubated at 37°C for 18 h. Other grampositive cocci were inoculated into tryptose phosphate broth. An inoculum of approximately 105 colony-forming units/ml was used to test isolates of gram-negative bacilli and S. aureus. For the other gram-positive cocci, an inoculum of 106 colony-fdrming units/ml was used for susceptibility testing.
All gram-negative bacilli used in this study were cultured from blood specimens obtained from patients hospitalized at The University of Texas M. D. Anderson Hospital between the years 1967 and 1976.
The majority of these patients had underlying malignant diseases. A total of 100 isolates each ofPseudomonas aeruginosa, Escherichia coli, Klebsiella spp., and Enterobacter spp., 64 isolates of Proteus spp., and 50 isolates of Serratia marcescens were utilized. All gram-positive cocci used in this study were cultured from hospitalized patients, most of whom did not havq underlying malignant diseases. A total of 41 isolates of Streptococcus pyogenes, 12 isolates of S. pneumoniae, and 50 isolates of S. aureus were studied. The susceptibility of isolates ofS. aureus to penicillin G was determined by means of the broth dilution technique. Those isolates inhibited by less than 0.10 Ag/ml were considered to be penicillin G susceptible, and those isolates resistant to more than 25 ,ug/ml were considered to be resistant to penicillin G. Isolates of gram-negative bacilli that had minimum inhibitory concentrations (MIC) of 12.5 ,.g or greater per ml were considered to be resistant to gentamicin.
Netilmicin, sisomicin, and gentamicin were supplied by Schering Corp., Bloomfield, N.J. Tobramycin and amikacin were supplied by Eli Lilly & Co., Indianapolis, Ind., and Bristol Laboratories, Division of Bristol-Myers Co., Syracuse, N.Y., respectively. Twofold serial dilutions of the antibiotics were made with appropriate broth, and the MIC was determined after incubation at 37°C for 18 h. The minimum bactericidal concentration (MBC) was defined as the lowest concentration of drug that yielded less than 25 colonies when 0.01 ml was subcultured onto sheep blood agar (less than five colonies per 0.001 ml of inoculum). A calibrated pipette was used to transfer the inoculum. All studies were performed in triplicate, and comparative studies were done simultaneously. shown in Fig. 1 . The MIC of netilmicin was 1.56 ,ug or less per ml against all isolates of Klebsiella spp., S. marcescens, and Enterobacter spp., 97% ofE. coli, 97% ofProteus mirabilis, 92% of indole-positive Proteus spp., and 94% of P. aeruginosa. All penicillin G-susceptible and penicillin G-resistant isolates of S. aureus strains were susceptible to netilmicin at a concentration of 0.05 ,ug or less per ml. Netilmicin inhibited 78% of the isolates ofS. pyogenes at a concentration of 3.12 ,ug/ml, whereas against S. pneumoniae it had no activity at this concentration.
RESULTS

The in vitro activity
In general, the MBC of most of the clinical isolates, with the exception of the S. marcescens isolates, equaled the MIC or was a twofold dilution greater. For example, the MBC was 1.56 ,ug/ml against 94% of isolates of E. coli, whereas the MIC was 0.78 ,ug/ml against 92%. For isolates ofS. marcescens, the MBC was six times greater than the MIC. Figure 2 shows a comparison of the in vitro activity of netilmicin with that of four other aminoglycosides: gentamicin sulfate, tobramycin, sisomicin, and amikacin against Enterobacteriaceae. Fig. 3 . At a concentration of 0.20 Amgl ml, sisomicin and tobramycin were the most active, both inhibiting 88% of the isolates. At the same concentration, netilmicin, gentamicin, and amikacin inhibited 70, 78, and 12%, respectively. All of the aminoglycosides inhibited over 90% of the isolates at a concentration of 3.12 ug/ml.
Twenty-three isolates of gram-negative bacilli known to be resistant to gentamicin, tobramycin, or sisomicin were tested for their susceptibility to netilmicin (Table 1 ). All six isolates of Klebsiella spp. were susceptible to netilmicin and amikacin. Some of these isolates were considerably more susceptible to netilmicin than to amikacin. Netilmicin was active against 80% of the isolates of Serratia spp. Two isolates of Serratia spp. were susceptible only to amikacin. Of the seven Pseudomonas isolates tested, four were equally susceptible to netilmicin and amikacin, two were resistant to netilmicin but susceptible to amikacin, and one was resistant to all five aminoglycosides.
DISCUSSION
Netilmicin is an aminoglycoside antibiotic with a broad-spectrum of activity against gramnegative bacilli and some gram-positive cocci. The in vitro activity of this antibiotic against gram-negative bacilli is similar to that of gentamicin sulfate. However, netilmicin was more active than other aminoglycosides against isolates of Klebsiella spp., Enterobacter spp., and 
